Golden Biotechnology Balance Sheet Health
Financial Health criteria checks 3/6
Golden Biotechnology has a total shareholder equity of NT$402.1M and total debt of NT$251.1M, which brings its debt-to-equity ratio to 62.5%. Its total assets and total liabilities are NT$714.2M and NT$312.1M respectively.
Key information
62.5%
Debt to equity ratio
NT$251.13m
Debt
Interest coverage ratio | n/a |
Cash | NT$210.89m |
Equity | NT$402.10m |
Total liabilities | NT$312.11m |
Total assets | NT$714.21m |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 4132's short term assets (NT$324.4M) exceed its short term liabilities (NT$285.5M).
Long Term Liabilities: 4132's short term assets (NT$324.4M) exceed its long term liabilities (NT$26.6M).
Debt to Equity History and Analysis
Debt Level: 4132's net debt to equity ratio (10%) is considered satisfactory.
Reducing Debt: 4132's debt to equity ratio has increased from 20.5% to 62.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4132 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 4132 has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.2% each year.